2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-180822
    COX-2-IN-63
    COX-2-IN-63 (Compound 6k) is an orally active COX-2 inhibitor with an IC50 of 0.89 μM. COX-2-IN-63 reduces the levels of inflammatory mediators PGE2, TNF-α, and IL-6. COX-2-IN-63 can effectively alleviate acute inflammation in a rat paw edema model and has a lower risk of gastrointestinal side effects. COX-2-IN-63 can be used in anti-inflammatory research.
    COX-2-IN-63
  • HY-180825
    Anticancer agent 292
    Anticancer agent 292 (Compound P4) is a photosensitizer for anti-melanoma. Anticancer agent 292 shows good biocompatibility under dark conditions and, upon illumination, induces apoptosis and partial necrosis in B16-F10 cells by disrupting the lysosomal membrane. Anticancer agent 292 not only directly kills tumor cells through the generation of reactive oxygen species (ROS), but also induces immune-prone cell death (ICD), thereby generating anti-tumor immune effects. Anticancer agent 292 can be used in the research of photodynamic therapy for melanoma.
    Anticancer agent 292
  • HY-180829
    HDAC6-IN-71 3062867-16-4
    HDAC6-IN-71 (Compound 24) is a HDAC6 inhibitor with IC50 values for HDAC6 and HDAC1 of 13.68 and 443.12 nM respectively. HDAC6-IN-71 effectively inhibits the production of NO by mouse macrophages, with its IC50 being 2.31 μM. HDAC6-IN-71 inhibits the HDAC6-NF-κB signaling pathway, reduces the levels of phosphorylated IκB-α and IKK-α/β, and suppresses the expression of downstream inflammatory proteins COX-2 and iNOS. HDAC6-IN-71 significantly alleviates ulcerative colitis in mice.
    HDAC6-IN-71
  • HY-180830
    NLRP3-IN-86 2361570-54-7 98%
    NLRP3-IN-86 (Compound 8a), a derivative of Songorine (HY-N2080), is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-86 can reduce LPS (HY-D1056)- and Nigericin (HY-127019)-stimulated lactate dehydrogenase (LDH) release (IC50 = 2.69 μM in THP-1 cells and 1.75 μ M in J774A.1 cells). NLRP3-IN-86 can inhibit gasdermin D (GSDMD) cleavage and IL-1β secretion. NLRP3-IN-86 can inhibit cell pyroptosis. NLRP3-IN-86 can be used for research of inflammation.
    NLRP3-IN-86
  • HY-180831
    BRD4 D1-IN-3
    BRD4 D1-IN-3 (compound 39) is a potent, selective, and cell-active BRD4-D1 inhibitor (IC50 = 39 nM, Ki = 2.4 nM) with >1700-fold selectivity over BRD2-D1. BRD4 D1-IN-3 reduces the expression of pro-inflammatory chemokines CXCL1 and CCL2 in an LPS (HY-D1056)-mediated cellular model of liver inflammation. BRD4 D1-IN-3 can be used for liver inflammation research.
    BRD4 D1-IN-3
  • HY-180889
    PROTAC BRD3 degrader-1 2257497-15-5 98%
    PROTAC BRD3 degrader-1 (compound D072) is a potent and selective PROTAC BRD3 degrader. PROTAC BRD3 degrader-1 selectively degrades BRD3 in mice, leading to the downregulation of H3K18ac without affecting BRD2 or BRD4. PROTAC BRD3 degrader-1 reduces intraocular inflammation in the experimental autoimmune uveitis (EAU) mouse mode and inhibits proinflammatory microglia in both uveitis retina and LPS (HY-D1056) treated mouse microglia cell line BV2. PROTAC BRD3 degrader-1 can be used for uveitis research.
    PROTAC BRD3 degrader-1
  • HY-180890
    PPARγ agonist-21
    PPARγ agonist-21 (Compound 9a) is a PPARγ agonist with an EC50 of 3.12 μM. PPARγ agonist-21 activates PPAR-γ to inhibit NF-κB and attenuate NLRP3 inflammasome assembly. PPARγ agonist-21 blocks NLRP3-ASC and NLRP3-NEK7 interaction. PPARγ agonist-21 attenuates the severity of gouty arthritis.
    PPARγ agonist-21
  • HY-180898
    AHL-7160 98%
    AHL-7160 is a covalent DGKα inhibitor that possesses dual functions of enzyme activity inhibition (IC₅₀ ≈ 12 nM) and molecular gel-mediated degradation. AHL-7160 can rapidly recruit endogenous DGKα to the cell membrane (EC₅₀ = 39 nM), and this effect has isozyme selectivity. AHL-7160 can stereospecifically block phosphatidylcholine acid (PA) production mediated by DGKα (IC₅₀ = 340 nM). AHL-7160 enhances T cell activation and promotes anti-tumor immune responses. AHL-7160 can be used for research on immunotherapy.
    AHL-7160
  • HY-180900
    Z3071585108 2249005-28-3
    Z3071585108 is a small molecule binder of the LAG-3 D1 domain with Kd values measured for the MST-TRIC channel and spectral shift detection of 59.2 and 56.1 μM respectively. Z3071585108 partially inhibits the binding of LAG-3 to MHCII, with an EC₅₀ of 42.9 μM. Z3071585108 can be used for the study of small molecule immunotherapies targeting LAG-3.
    Z3071585108
  • HY-180901
    BRD3 ligand-1 2257497-24-6
    BRD3 ligand-1 is a target protein ligand that can be used for the synthesis of PROTACs, such as PROTAC BRD3 degrader-1 (HY-180889).
    BRD3 ligand-1
  • HY-180902
    Pomalidomide-C11-azide 2296708-57-9
    Pomalidomide-C11-azide is a synthetic E3 ligase ligand-linker conjugate, which can be used for the synthesis of PROTAC BRD3 degrader-1 (HY-180889).
    Pomalidomide-C11-azide
  • HY-180939
    LFA-1-IN-2
    LFA-1-IN-2 (Compound 25) is a potent LFA-1 inhibitor with a Kd of 21.46 μM. LFA-1-IN-2 inhibits ICAM-1-mediated cell adhesion. LFA-1-IN-2 protects cells from inflammatory hyperosmotic stress. LFA-1-IN-2 improves dry eye disease.
    LFA-1-IN-2
  • HY-180947
    IL-17-IN-5 3103740-63-9
    IL-17-IN-5 (Compound 3) is an IL-17 inhibitor with an IC50 of <0.1 μM. IL-17-IN-5 can be used in the research of inflammatory diseases.
    IL-17-IN-5
  • HY-180952
    Zaltoprofen sulfoxide 134085-79-3 98%
    Zaltoprofen sulfoxide (Compound M2) is the main metabolite of Zaltoprofen (HY-B0619). Zaltoprofen sulfoxide is an efficient and selective COX-2 inhibitor (IC50 = 45.38 nM) and a PPAR-γ activator. Zaltoprofen sulfoxide effectively inhibits NF-κB and MAPK inflammatory signaling pathways and alleviates acute lung injury induced by LPS (HY-D1056B3). Zaltoprofen sulfoxide can be used for the study of acute lung injury.
    Zaltoprofen sulfoxide
  • HY-181008
    Antitubercular agent-56
    Antitubercular agent-56, a Questiomycin A (HY-N8439) derivative, is a potent and orally active antitubercular agent. Antitubercular agent-56 disrupts mycobacterial envelope integrity by inhibiting FabD (Kd = 9.39 μM; IC50 = 49.60 μM). Antitubercular agent-56 exhibits good intracellular antimycobacterial activity against Mycobacterium tuberculosis (MTB) and drug-resistant MTB both in vitro and in vivo. Antitubercular agent-56 can be used for research on tuberculosis (TB).
    Antitubercular agent-56
  • HY-181014
    Glucocorticoid receptor modulator 5
    Glucocorticoid receptor modulator 5 (Compound D8) is a selective, orally active Glucocorticoid receptor modulator. Glucocorticoid receptor modulator 5 shows extremely high transrepression activity (TRNF-κB IC50 = 0.0009 μM, TRAP-1 IC50 = 0.0005 μM). Glucocorticoid receptor modulator 5 exerts its anti-inflammatory activity by interacting directly with the Glucocorticoid receptor signaling pathway. Glucocorticoid receptor modulator 5 significantly alleviates dermatitis and autoimmune hepatitis.
    Glucocorticoid receptor modulator 5
  • HY-181028
    Tyrosinase-IN-48 98%
    Tyrosinase-IN-48 (Compound 3) is a potent and competitive chalcone-based tyrosinase inhibitor with an IC50 of 0.49 μM. Tyrosinase-IN-48 has potent antioxidant potential with significant DPPH and ABTS radical scavenging capacity. Tyrosinase-IN-48 can chelate the binuclear copper ions in the active center of tyrosinase and reduce Cu2+ to Cu+, thereby reducing the catalytic activity of the enzyme. Tyrosinase-IN-48 has low cytotoxicity for HEK293 cells and zebrafish embryo. Tyrosinase-IN-48 shows antibrowning effects to improve food quality and can be used for research of food preservation.
    Tyrosinase-IN-48
  • HY-181029
    Tyrosinase-IN-49 98%
    Tyrosinase-IN-49 (Compound 12) is a potent and mixed-type chalcone-based tyrosinase inhibitor with an IC50 of 0.19 μM. Tyrosinase-IN-49 has potent antioxidant potential with significant DPPH and ABTS radical scavenging capacity. Tyrosinase-IN-49 can chelate the binuclear copper ions in the active center of tyrosinase and reduce Cu2+ to Cu+, thereby reducing the catalytic activity of the enzyme. Tyrosinase-IN-49 has low cytotoxicity for HEK293 cells and zebrafish embryo. Tyrosinase-IN-49 shows antibrowning effects to improve food quality and can be used for research of food preservation.
    Tyrosinase-IN-49
  • HY-181040
    Factor B-IN-8 3049710-19-9 98%
    Factor B-IN-8 (Compound (3R ,4R )-15) is a potent, selective and orally active factor B inhibitor with an IC50 of 10.2 nM. Factor B-IN-8 can effectively inhibit the binding of factor B to C3b and the subsequent formation of C3 convertase (C3bBb). Factor B-IN-8 can inhibit the deposition of membrane attack complex (MAC) mediated by alternativepathway with an IC50 of 59.3 nM. Factor B-IN-8 can reduce the cleavage of factor B protein and decrease the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 can be used for researches of arthritis and paroxysmal nocturnal hemoglobinuria (PNH).
    Factor B-IN-8
  • HY-181044
    COX-2/5-LOX-IN-6
    COX-2/5-LOX-IN-6 (Compound 4c) is a potent and selective 5-LOX (IC50 = 0.10 μM) and COX-2 (IC50: 2.88 μM) inhibitor. COX-2/5-LOX-IN-6 displays potent anticancer activity against ovarian cancer. COX-2/5-LOX-IN-6 would not cause cytotoxic effects in noncancerous cells. COX-2/5-LOX-IN-6 is a potential anti-inflammatory agent.
    COX-2/5-LOX-IN-6
Cat. No. Product Name / Synonyms Application Reactivity